RegMed Investors’ (RMi) pre-open: Fits and starts

August 25, 2025 7:53am

The Russell 2000 is up about 6.7% since the start of August and 4.5% over the past year. The Healthcare (XLV) is 1 of the leading the sector action after lagging for most of this year

Just as the September re-balancing is to begin and funds seek to post and protect any upside %’s

I expect some sentiment selling as we get closer to August’s month end and to the Labor Day holiday

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

The sector is what it is, until it isn’t and even then, it doesn’t seem to be …

Pre-open (my) Signals: 3 SELL into Strength and 3 Positive Indications

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

Friday’s night’s … RegMed Investors (RMi):  Sector rises after suggestions of interest rate cuts ahead … https://www.regmedinvestors.com/articles/14075

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

Monday: The pre-open Dow futures are DOWN -0.31% or (-140 points), the S&P futures are DOWN -0.29% or (-18 points) and the Nasdaq futures are DOWN -0.38% or (-88 point)

• U.S. equity futures traded in negative territory Monday
• European markets trade lower,
• Asia Pacific markets climbed closing higher.

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

• Friday: The Dow closed UP +846.24 points or +1.89%, the S&P closed UP +96.75 points or +1.52% while the Nasdaq closed UP +396.223 points or +1.88%
• Thursday: The Dow closed DOWN -152.81 points or -0.34%, the S&P closed DOWN -25.61 points or -0.40% while the Nasdaq closed DOWN -72.545 points or -0.34%
• Wednesday: The Dow closed UP +16.04 points or +0.04%, the S&P closed DOWN -15.59 points or -0.24% while the Nasdaq closed DOWN -142.095 points or -0.67%
• Tuesday: The Dow closed UP +10.45 points or +0.02%, the S&P closed DOWN -37.78 points or -0.59% while the Nasdaq closed DOWN – 314.82 points or -1.46%
• Monday: The Dow closed DOWN -34.30 points or -0.08%, the S&P closed DOWN -0.65 points or -0.01% while the Nasdaq closed UP +6.797 points or +0.03%
• Last week, the Dow advanced +1.5%, the S&P 500 +0.3%, while the Nasdaq slipped -0.6%.
• The previous week, the S&P 500 was up +0.9%. the Nasdaq is up +0.8% and the Dow +1.7%

Economic Data Docket: Chicago Fed activity index, July (-0.10 prior); New home sales, month-over-month, July (+0.1% expected, +0.6% prior); Dallas Fed manufacturing activity, August (+0.9 prior); New home sales, month over month, July (+0.1% expected, +0.6% prior) and 2 fed president speeches                               

Q3 – August - 7 negative and 8 positive closes

•             July – 1 market holiday, 13 positive and 9 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• I’ll pass; …. an escape from this week’s econs and more earnings releases, and the usual ups, downs and just plain uncertainty

Although:

• Supernus Therapeutics (SUPN) closed up +$1.56 after Thursday’s +$0.64, Wednesday’s +$0.68, Tuesday’s -$0.99 and Monday’s +$0.30 with a neutral pre-open - SELL into Strength
• CRISPR Therapeutics (CRSP0 closed up +$1.50 after Thursday’s -$0.25, Wednesday’s -$1.09, Tuesday’s -$3.43 and Monday’s -$2.14 with a positive +$0.38 or +0.70% pre-open
• Lenz Therapeutics (LENZ0 closed up +$0.15 after Thursday’s +$1.31, Wednesday’s +$0.93, Tuesday’s -$1.16 and last Monday’s +$0.92 with a neutral pre-open - SELL into Strength
• Precigen (PGEN) closed up +$0.54 after Thursday’s +$0.43 with a positive +$0.06 or +1.44% pre-open - SELL into Strength
• Beam Therapeutics (BEAM) up +$0.63 after Thursday’s -$0.05, Wednesday’s -$0.29, Tuesday’s -$0.75 and Monday’s -$0.72 with a positive +0.22 or +1.32% pre-open
• Ionis Pharmaceuticals (IONS) closed down -$0.55 after Thursday’s +$0.42, Wednesday’s +$0.33, Tuesday’s -$0.95 and last Monday’s -$0.35 with a positive +$0.61 or +1.43% pre-open

The BOTTOM LINE: After slump earlier in the week, a huge surge followed Powell's comments in Jackson Hole left indexes and the cell and gene therapy sector roaring.

• During what was likely his final speech at the Jackson Hole Symposium as Fed chair, Jerome Powell told the audience the "shifting balance of risks may warrant adjusting our policy stance." For investors, the words "may warrant" became a green light on rate cuts next month. <Yahoo Finance>

Downside risks are on the table … as September’s fund rebalancing and forthcoming rotations.

• I expect some sentiment selling as we get closer to August’s month end and to Labor Day

Putting to the test on the coming Friday with the release of the Personal Consumption Expenditures (PCE) index, the Fed's preferred inflation measure.

• Expect core PCE inflation to peak slightly above 3% by the end of the year. With inflation drifting in the wrong direction and the labor market losing momentum, the Fed faces difficult trade-offs in balancing its dual mandate."

August: understand the “flow” … Last week

• 8/22 – Friday closed positive with 30 positive, 4 negative and 1 flat
• 8/21 – Thursday closed positive with 22 positive, 12 negative and 1 flat
• 8/20 - Wednesday closed negative with 14 positive, 19 negative and 2 flats
• 8/19 - Tuesday closed negative with 5 positive, 28 negative and 2 flats
• 8/18 - Monday closed positive with 18 positive, 17 negative and 0 flat

A problem in the week, “Fed minutes from the late July meeting show policymakers divided between inflation and labor market concerns as tariffs complicate the central bank's job. Fed chief Jerome Powell will give his final Jackson Hole speech on Friday morning.” <IBD>

Earnings are still the highlight of the week: Meeting earnings expectation and/or missing consensus will deem share pricing outcomes.

• Earnings:  4 net incomes and 25 net losses of 29 releases to date

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

• As always, I brace myself for earnings associated with share pricing volatility, some economics and tariff developments and their effects?

Welcome to my world of defining the “grey’ in our universe!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

 I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.